Scienture (SCNX) News Today $1.21 -1.01 (-45.50%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.19 -0.02 (-1.65%) As of 08/14/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock Why Is Scienture Dropping Today?Toggle Visibility of Why Is Scienture Dropping Today?Scienture Holdings, Inc. (NASDAQ: SCNX) shares have moved lower after the company announced a dilutive registered direct offering, though offset by a key commercial milestone for its new hypertension treatment. Positive Sentiment: Shipment of launch quantities of Arbli™ (losartan potassium) oral suspension to its distribution center marks the first commercial rollout of the FDA-approved liquid formulation. Scienture announces shipment of Arbli Oral Suspension Negative Sentiment: Shares declined after Scienture priced 3.23 million shares at $1.20 in a registered direct offering to raise approximately $3.9 million, diluting existing equity. Scienture prices 3.23M shares at $1.20 Negative Sentiment: Stock plummeted following the announcement of the $3.9 million discounted offering, highlighting investor concerns over dilution and near-term capital needs. Scienture stock plummets after offering Posted 3h agoAI Generated. May Contain Errors. SCNX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Scienture prices 3.23M shares at $1.20 in registered direct offeringAugust 14 at 6:18 PM | msn.comScienture stock plummets after announcing $3.9 million registered offeringAugust 14 at 11:36 AM | investing.comScienture Shares Plunge After $3.9 Million Discounted Offering AnnouncementAugust 14 at 11:36 AM | msn.comScienture Holdings, Inc. Announces Pricing of $3. ...August 14 at 9:18 AM | gurufocus.comScienture Holdings, Inc. Announces $3.9 Million Registered Direct Offering of Common StockAugust 14 at 9:18 AM | quiverquant.comQScienture Holdings, Inc. Announces Pricing of $3. ...August 14 at 9:18 AM | gurufocus.comScienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common StockAugust 14 at 9:00 AM | globenewswire.comScienture announces shipment of launch quantities of Arbli Oral SuspensionAugust 13 at 1:17 PM | msn.comScienture Holdings, Inc. to Launch Arbli™ Oral Suspension for Hypertension Treatment in the U.S. marketAugust 13 at 8:38 AM | quiverquant.comQSCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.August 13 at 8:05 AM | globenewswire.comScienture (NASDAQ:SCNX) Upgraded to "Hold" at Wall Street ZenAugust 11, 2025 | americanbankingnews.comScienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding | SCNX Stock NewsJuly 24, 2025 | gurufocus.comScienture Holdings Secures $1.2 Million in Capital RaiseJuly 24, 2025 | tipranks.comScienture Holdings, Inc. Secures $3 Million Bridge Funding to Support Product Launches and Pipeline DevelopmentJuly 24, 2025 | quiverquant.comQScienture Holdings, Inc. Obtains $1.2 Million in Bridge FundingJuly 24, 2025 | globenewswire.comScienture Holdings, Inc. Regains Compliance with Nasdaq Listing ...July 18, 2025 | nasdaq.comScienture Holdings Inc News (SCNX) - Investing.comJuly 18, 2025 | investing.comScienture Holdings, Inc. Regains Compliance with Nasdaq Listing RequirementsJuly 16, 2025 | globenewswire.comScienture Holdings Secures Indemnification for LeadershipJuly 3, 2025 | tipranks.comScienture Holdings Announces Cancelation of ELOCJune 17, 2025 | globenewswire.comSCIENTURE Announces Executive Leadership TransitionMay 22, 2025 | globenewswire.comSCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.May 19, 2025 | globenewswire.comScienture initiates supply chain activities by subsidiary to launch ArbliApril 24, 2025 | markets.businessinsider.comScienture Holdings, Inc. Announces Supply Chain Readiness for Launch of FDA-Approved ArbliTM Oral Suspension in July 2025April 22, 2025 | quiverquant.comQSCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.April 22, 2025 | globenewswire.comScienture Holdings Divests Subsidiaries to Tollo HealthApril 11, 2025 | tipranks.comSCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment ...April 10, 2025 | seekingalpha.comScienture divests Integra Pharma Solutions, Bonum Health, Softell for $5MApril 10, 2025 | markets.businessinsider.comSCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.April 8, 2025 | globenewswire.comScienture files to sell 2.64M shares of common stock for holdersApril 5, 2025 | markets.businessinsider.comScienture CEO says focused on execution, growth, expansion for years aheadApril 4, 2025 | markets.businessinsider.comScienture Holdings, Inc. Issues Annual Letter to ShareholdersApril 3, 2025 | globenewswire.comSCNX Scienture Holdings, Inc.April 2, 2025 | seekingalpha.comScienture appoints Rath as CCO, enters agreement with SyneosMarch 25, 2025 | markets.businessinsider.comSCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales OrganizationMarch 25, 2025 | globenewswire.comScienture announces draaw on Equity Line of CreditMarch 20, 2025 | markets.businessinsider.comScienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading DaysMarch 19, 2025 | globenewswire.comScienture announces U.S. FDA approval of NDA for SCN-102March 19, 2025 | markets.businessinsider.comSCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.March 18, 2025 | globenewswire.comSCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.March 6, 2025 | globenewswire.comScienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of XenobioticsJanuary 21, 2025 | globenewswire.comScienture Holdings, Inc. Announces Participation in The Microcap Conference 2025December 17, 2024 | globenewswire.comScienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041December 10, 2024 | globenewswire.com Get Scienture News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address SCNX Media Mentions By Week SCNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SCNX News Sentiment▼0.370.61▲Average Medical News Sentiment SCNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SCNX Articles This Week▼131▲SCNX Articles Average Week Get Scienture News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MMLP News Today NHTC News Today GDC News Today RAVE News Today COSM News Today CGTL News Today DTCK News Today HYFM News Today BANL News Today FXLV News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SCNX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scienture Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scienture With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access